Back to Journals » HIV/AIDS - Research and Palliative Care » Volume 1 » Default

Profile of darunavir in the management of treatment-experienced HIV patients

Authors Wolfe C, Hicks C

Published 29 September 2009 Volume 2009:1 Pages 13—21


Review by Single anonymous peer review

Peer reviewer comments 2

Cameron Wolfe, Charles Hicks

Duke University Medical Center, Division of Infectious Diseases, Durham, NC, USA

Abstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.

Keywords: darunavir, HIV, ritonavir

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]